[go: up one dir, main page]

MX2018011300A - Composiciones y metodos para el tratamiento de la presbicia. - Google Patents

Composiciones y metodos para el tratamiento de la presbicia.

Info

Publication number
MX2018011300A
MX2018011300A MX2018011300A MX2018011300A MX2018011300A MX 2018011300 A MX2018011300 A MX 2018011300A MX 2018011300 A MX2018011300 A MX 2018011300A MX 2018011300 A MX2018011300 A MX 2018011300A MX 2018011300 A MX2018011300 A MX 2018011300A
Authority
MX
Mexico
Prior art keywords
compositions
presbyopia
treatment
methods
preservative
Prior art date
Application number
MX2018011300A
Other languages
English (en)
Inventor
Horn Gerald
NORDAN Lee
Original Assignee
Presbyopia Therapies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/073,089 external-priority patent/US9844537B2/en
Priority claimed from US15/073,139 external-priority patent/US9833441B2/en
Priority claimed from US15/235,431 external-priority patent/US10052313B2/en
Application filed by Presbyopia Therapies Llc filed Critical Presbyopia Therapies Llc
Publication of MX2018011300A publication Critical patent/MX2018011300A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La invencion proporciona composiciones y metodos para el tratamiento de la presbicia y otros defectos de la vision; las composiciones comprenden preferiblemente aceclidina y un poliol y/o un agente cicloplejico; las composiciones contienen opcionalmente un agente tensoactivo, un potenciador de la viscosidad, un modificador de la osmolaridad y un conservador.
MX2018011300A 2016-03-17 2017-03-08 Composiciones y metodos para el tratamiento de la presbicia. MX2018011300A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15/073,089 US9844537B2 (en) 2013-08-28 2016-03-17 Compositions and methods for the treatment of presbyopia
US15/073,139 US9833441B2 (en) 2013-08-28 2016-03-17 Compositions and methods for the treatment of presbyopia
US15/235,431 US10052313B2 (en) 2013-08-28 2016-08-12 Compositions and methods for the treatment of presbyopia
PCT/US2017/021244 WO2017160548A1 (en) 2016-03-17 2017-03-08 Compositions and methods for the treatment of presbyopia

Publications (1)

Publication Number Publication Date
MX2018011300A true MX2018011300A (es) 2019-02-18

Family

ID=59852351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011300A MX2018011300A (es) 2016-03-17 2017-03-08 Composiciones y metodos para el tratamiento de la presbicia.

Country Status (6)

Country Link
EP (1) EP3429584A4 (es)
JP (1) JP2019508472A (es)
CN (1) CN108883102A (es)
CA (1) CA3017755A1 (es)
MX (1) MX2018011300A (es)
WO (1) WO2017160548A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11026884B2 (en) * 2018-01-24 2021-06-08 Eye Therapies Llc Methods for improving vision
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
BR112021006618B1 (pt) * 2018-10-10 2022-09-27 Presbyopia Therapies, Inc Composições e métodos para o tratamento da presbiopia
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
WO2021021644A1 (en) * 2019-07-26 2021-02-04 Allergan Sales, Llc Compositions and methods for treatment of presbyopia
CA3195784A1 (en) * 2020-11-02 2022-05-05 Rhett Mead SCHIFFMAN Degradant compound in a medicament
CN116583277A (zh) * 2020-11-02 2023-08-11 视觉治疗股份有限公司 药物中的降解化合物
CN118541148A (zh) 2021-11-10 2024-08-23 视觉治疗股份有限公司 增强抗老花眼作用的碳酰胆碱制剂
EP4433053A4 (en) 2021-11-17 2025-09-17 Lenz Therapeutics Operations Inc ACECLIDINE DERIVATIVES, THEIR COMPOSITIONS AND METHODS OF USE
CN114588156B (zh) * 2022-04-22 2024-06-11 温州医科大学附属眼视光医院 一种眼用制剂及其在治疗老花眼中的应用
US12414942B1 (en) * 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120758A (en) * 1998-07-16 2000-09-19 Shaklee Corporation Preservative system for topically applied products
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9314427B2 (en) * 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US10052313B2 (en) * 2013-08-28 2018-08-21 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
CA2934453A1 (en) * 2013-12-18 2015-06-25 Gnt, Llc Compositions and methods for treatment of glaucoma

Also Published As

Publication number Publication date
CA3017755A1 (en) 2017-09-21
WO2017160548A1 (en) 2017-09-21
CN108883102A (zh) 2018-11-23
EP3429584A4 (en) 2019-11-13
EP3429584A1 (en) 2019-01-23
JP2019508472A (ja) 2019-03-28

Similar Documents

Publication Publication Date Title
MX2018011300A (es) Composiciones y metodos para el tratamiento de la presbicia.
EP4385521A3 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
EP4563162A3 (en) Compositions and methods for the treatment of presbyopia
MX2021003819A (es) Moduladores de alfa-1 antitripsina.
MX2017005260A (es) Bifidobacterias activadas y metodos de uso de las mismas.
MY186271A (en) Ophthalmic compositions and methods of use therefor
GB2537078A (en) Settable compositions and uses thereof
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2017007852A (es) Formulaciones de acido hipocloroso y metodos para tratar afecciones de la piel.
EP4628631A3 (en) Conditional primer extension for single-molecule detection
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12017500870A1 (en) Polymer composition comprising basic additive, process and articles comprising said polymer composition
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
WO2016167944A8 (en) Compositions and methods for treating autism
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
GB2543723A (en) Polyphenol compositions
MX2017005183A (es) Metodo de tratamiento para antibrote de tuberculos con cantidad reducida de cipc.
PH12018500118A1 (en) Antitussive compositions and methods
HK1250145A1 (zh) 治疗多发性骨髓瘤的组合物和方法
PH12019502380A1 (en) Compositions and methods for treating retinopathy
HK1248567A1 (zh) 治疗急性髓性白血病的组合物和方法
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
WO2016100745A3 (en) Methods and compositions related to transplant-associated thrombotic microangiopathy
WO2016046759A3 (en) Compositions and methods for treating friedreich's ataxia